To predict volume of distribution at steady-state (V ss ), empirical (e.g., allometry) and mechanistic (using physicochemical property data and plasma protein binding) methods have been used. None of these approaches has been able to predict V ss accurately for the total compliment of a wide range of drugs. Therefore, alternative approaches would be of value. This study evaluates the utility of in vitro nonspecific tissue-binding measurements in predicting V ss for a wide range of drugs in rats. Literature as well as proprietary compounds were studied. It was found that in vitro tissue-binding measurements combined with calculated effects of the pH partition hypothesis often predict V ss more accurately than other available mechanistic methods and that this approach can compliment existing methods. The V ss values for some compounds were not accurately predicted using either nonspecific tissue-binding experiments or other available mechanistic methods. The V ss for these drugs may not be describable by nonspecific tissue binding alone; there may be significant specific components to the mechanism of distribution for these drugs, such as pH-dependent uptake into lysosomes (primarily strongly basic drugs), active transport, and/or enterohepatic recirculation. A lack of prediction for certain drugs warrants further investigation into these mechanisms and their application to more accurate prediction of V ss by mechanistic means.
The apparent volume of distribution at steady state (V ss ) is one of the primary descriptive terms derived from pharmacokinetic (PK) analysis of the concentration-time profile after intravenous administration of drugs. V ss affects the shape of the concentration-time curve. Whereas clearance (CL) and bioavailability (F) determine the extent of drug exposure, V ss , together with CL, determines t 1/2 and thus the duration of exposure for a compound. During the drug discovery and development process, to achieve appropriate drug exposure and duration of coverage and to maximize efficacy and minimize potential toxicity, CL, V ss , t 1/2 , and F are routinely evaluated through small-molecule medicinal chemistry and PK screening efforts. Early in this process, PK testing of drug candidates is performed in vitro and in animals with the hopes of translating these results into an assessment of the potential for success in humans and ultimately to choose the best drug candidates for clinical study (Lin and Lu, 1997; Singh, 2006) .
A variety of techniques are applied to predict animal and human PK properties. Empirical approaches, such as interspecies scaling, have been used to establish an allometric relationship between the PK parameters of a drug observed in animals and another parameter that is readily observable, such as body weight (Boxenbaum, 1982) . Assuming that the PK parameters scale well with basic physiological characteristics such as body size and blood flow, the extrapolation of human PK is attempted. Although this approach is widely used in the drug discovery setting, it often results in mixed success, with little opportunity for explanation of unsuccessful predictions (Fagerholm, 2007; Sinha et al., 2008) . This result is probably due to a lack of consideration (or an underappreciation) by these approaches of the potential for species differences in unscalable biochemical properties such as metabolic enzyme activity, transporter expression, drug binding to proteins in blood or tissues, or other specific mechanisms of drug disposition (Lin, 1998 (Lin, , 2006 . Although retrospective studies have indicated that the prediction accuracy of empirically based approaches can be improved by introducing an assortment of empirical rules, molecular descriptors, or in vitro and physiological correction factors to allometric relationships, it is difficult to surmise a priori which of these empirical approaches or correction factors would best apply to a novel compound under investigation (Nagilla and Ward, 2004; Fagerholm, 2007; Sinha et al., 2008; Hosea et al., 2009) .
With this in mind, many PK experts have lauded more mechanistic and physiologically based modeling and prediction techniques as being conceptually superior (Nestorov, 2003 (Nestorov, , 2007 Rowland et al., 2004) . These approaches are envisioned to integrate compound-specific properties derived in vivo or in vitro, such as protein binding, enzyme kinetics, membrane permeability, physicochemical properties, and tissue partitioning, into a PK model built around well characterized compound-independent physiological information such as organ volume, tissue composition, blood flow, and enzyme distribution. In this way the predictive model can remain constant; only the species-dependent physiological parameters and the experimentally determined compound data need be changed (Theil et al., 2003; Jones et al., 2006; De Buck et al., 2007) . Such concepts have led to the wide use of in vitro metabolism data in predicting hepatic CL in animals and humans (Riley et al., 2005; Rostami-Hodjegan and Tucker, 2007) , for which even inaccurate predictions can yield insight into mechanisms of disposition and indicate areas for further study.
Mechanistic approaches to predicting tissue concentrations and V ss have focused on the concept that the apparent distribution of a drug can be predominantly explained by relative partitioning, or nonspecific binding, of the drug to various components of blood and tissues. The extent of distribution to each type of tissue is therefore expected to vary, depending on the differences in tissue composition. On this basis, tissue composition equations that use drug plasma protein binding, lipophilicity, and pK a to estimate the potential extent of partitioning into tissue components such as tissue water, albumin, neutral lipids, and neutral phospholipids, were proposed by Poulin and Theil (2002) and corrected by Berezhkovskiy (2004) , leading to a prediction of drug distribution. A revised model was then developed that, in addition to the previous concepts, estimated interactions with acidic phospholipids for basic drugs, estimated interactions with tissue components based on drug partitioning into red blood cells, and considered blood-to-tissue pH gradients per the pH partition hypothesis (Rodgers et al., 2005; Rodgers and Rowland, 2006) . These two models were incorporated into the physiologically based PK prediction software Simcyp (version 8.0; Simcyp Ltd., Sheffield, UK), therein named method 1 and method 2, respectively. As mentioned, these models rely on estimates of nonspecific tissue binding from physicochemical property data and assume that binding to these gross classes of tissue components prevail in the determination of V ss . Studies to determine the extent of tissue binding in vitro using tissue homogenates, slices, or chunks, which could better represent tissue binding in vivo, have also been attempted. For example, Lin et al. (1982) successfully incorporated in vitro tissue binding measurements into a physiological model of ethoxybenzamide. More recently, an approach to estimate brain penetration of drugs using binding experiments conducted with homogenates of brain tissue has been described previously (Kalvass et al., 2007) . Furthermore, historically, some comparative studies have been conducted on the properties of drug binding to tissues (Kurz and Fichtl, 1983; Schuhmann et al., 1987; Clausen and Bickel, 1993; Ballard et al., 2003) . However, a study on the ability to use in vitro tissue-binding experiments to quantitatively predict the V ss of a wide range of drugs has not been conducted. Such a study would serve to complement other reported mechanistic approaches to predicting drug distribution and is the purpose of the present report.
Materials and Methods

Materials.
Test compounds (TC1-TC9) were synthesized at Amgen, Inc. (Cambridge, MA). Other compounds were obtained from commercial sources as appropriate. Rat whole blood and plasma were purchased from Bioreclamation, Inc. (Hicksville, NY).
Animals. Sprague-Dawley rats, 7 to 8 weeks of age, were obtained from Charles River Laboratories, Inc. (Wilmington, MA). Rats were maintained in a temperature-and humidity-controlled environment and in a 12-h light/dark cycle at Amgen Inc. All study procedures involving animals were conducted under protocols approved by the Amgen Institutional Animal Care and Use Committee.
Pharmacokinetic Studies in Male Rats. Each test compound (TC1-TC9) was administered intravenously to male rats (n ϭ 3) at a dose of 0.25 mg/kg formulated in 100% dimethyl sulfoxide. Animals were given no more than 0.5 ml of dimethyl sulfoxide per kg. Blood samples were collected before the dose and at 5, 15, and 30 min and 1, 2, 4, 6, 8, and 24 h after the dose. Blood samples were processed for plasma. The analytes were extracted from plasma by addition of 5 volumes of acetonitrile containing an appropriate internal standard. The samples were centrifuged, and the supernatants were diluted with an equal volume of water. Extracted samples were quantitated against a standard curve on the liquid chromatography (LC)-tandem mass spectrometry (MS/MS) system described below. Noncompartmental pharmacokinetic parameters were calculated using Small Molecules Discovery Assay Watson (version 7.0.0.01; Thermo Fisher Scientific, Waltham, MA) using the linear/log trapezoidal method.
Preparation of Rat Tissues. Untreated rats were euthanized by CO 2 asphyxiation. The rats were perfused with phosphate-buffered saline (PBS) via the left ventricle using a peristaltic minipump. PBS was perfused at a rate of 25 ml/min for up to 10 min in whole-body perfusions. Isolated organs were additionally perfused at lower rates as necessary to remove residual blood. Intestinal tissue was flushed of contents with PBS. Skin samples were shaved. The tissue samples were weighed. Rat lung, brain, heart, bone (femurs), thymus, kidneys, testes, liver, spleen, pancreas, and whole intestine were each added to 2 volumes of PBS, assuming that 1 g of tissue equals 1 ml. Muscle (quadriceps), adipose tissue (abdominal), and skin were cut into small pieces using razor blades and added to 4, 4, and 9 volumes of PBS adjusted to pH 7.0, respectively. The tissues were homogenized using a Power Gen 125 homogenizer equipped with a 10 ϫ 95-mm homogenizer probe (Thermo Fisher Scientific). Tissue homogenates were stored at Ϫ80°C until used.
Determination of Fraction Unbound in Plasma and Tissues. Fractions unbound in rat plasma (f up ) and tissue (f ut ) were determined in triplicate using an ultracentrifugation technique. Blank matrix (i.e., plasma or tissue homogenates) was spiked with compound to achieve a final concentration of 5 M and was centrifuged at 600,000g for 5 h at 37°C (plasma) or 5°C (tissue). Halfway through the spin, at 2.5 h, the topmost (lipid) layer was removed by aspiration. After the complete 5-h spin, aliquots of the middle (water) layer were transferred into an equal volume of blank matrix and extracted with 5 volumes of acetonitrile containing internal standard. Aliquots of the original spiked matrix were mixed with an equal volume of blank matrix and 2 volumes of plasma ultrafiltrate (plasma) or PBS (tissue) and extracted with 10 volumes of acetonitrile. Extracts were centrifuged to precipitate proteins and analyzed with the LC-MS/MS method described below. Observed fraction unbound was calculated from the ratio of concentration observed in the water layer after centrifugation relative to total concentration in original spiked matrix. The observed fraction unbound in tissues was corrected for the dilution occurring during homogenization, according to eq. 1 as described by Kalvass et al. (2007) :
where f u 2 is the observed fraction unbound in tissues, f u 1 is the estimated fraction unbound assuming no dilution, and D is the -fold dilution of the tissue. Determination of BP. BP was determined in vitro after incubation of compound in fresh whole blood. Blood was warmed to 37°C and compound was spiked to a concentration of 1 M. After incubation for 1 h the blood samples were processed for plasma. Reference plasma was also spiked with compound to a concentration of 1 M. Samples were extracted with 6 volumes of acetonitrile containing internal standard, centrifuged, and analyzed on the LC-MS/MS system described below. BP was calculated by dividing the peak area observed in the reference plasma (representing nominal blood concentration) by the peak area observed in the treated plasma (representing plasma concentration).
Sample Analysis. Sample extracts from in vitro and in vivo experiments were analyzed by multiple reaction monitoring on an LC-MS/MS system consisting of dual Shimadzu LC-10AD high-performance liquid chromatography pumps and a DGU-14A degasser (Shimadzu, Columbia, MD), a CTCPAL autoinjector (Leap Technologies, Carrboro, NC), and an API3000 or API4000 LC-MS/MS system, equipped with an electrospray ion source and operated by the Analyst software package (Applied Biosystems, Foster City, CA). Chromatography was conducted on a Sprite Armor C18 (20 ϫ 2.1 mm, 10 m) analytical column (Analytical Sales and Products, Pompton Plains, NJ) with a 0.5-m PEEK guard filter, using the following mobile-phase gradient program: mobile phase A (MPA) ϭ H 2 O with 0.1% formic acid; mobile phase B (MPB) ϭ acetonitrile with 0.1% formic acid; 0 min ϭ 98% MPA, 2% MPB; 0.3 min ϭ 98% MPA, 2% MPB; 0.7 min ϭ 5% MPA, 95% MPB; 1.3 min ϭ 5% MPA, 95% MPB; 1.4 min ϭ 98% MPA, 2% MPB; 1.7 min ϭ end of run; approximately 2 min between sample injections. For the first 0.5 min of each sample run, the LC eluent was diverted from the ion source to waste. Each compound was detected in either positive or negative ion mode after tuning the mass spectrometer electronics to the mass transition with the largest intensity.
Calculation of Fraction Un-Ionized in Blood and Tissues. Physicochemical properties of the compounds were calculated using ACD/Labs (version 8.0; Advanced Chemistry Development, Inc., Toronto, ON, Canada). The fractions un-ionized in blood (f uib ) and tissues (f uit ) were calculated according to equations derived from the Henderson-Hasselbalch equation. The pH values of blood and intracellular tissue water were taken to be 7.4 and 7.0, respectively, as suggested in other publications (Roos and Boron, 1981; Harashima et al., 1984; Rodgers et al., 2005) . Figure 1 shows the calculation scheme.
Calculation of Predicted V ss . Predicted V ss was calculated assuming that V ss is determined predominantly by 1) relative nonspecific binding to components of blood and tissues and 2) pH gradients between intra-and extracellular spaces and that 3) rapid equilibrium between blood and tissue occurs (i.e., good permeability), 4) drug distributes relatively uniformly within each organ, 5) active transport does not contribute significantly to distribution, and 6) distributive processes are nonsaturating. Predicted blood V ss was calculated by using the tissue-binding data according to the following form of the Oie-Tozer equation (eq. 2):
where V b is the total volume of blood, V Tn is the total volume of each tissue, and K pTn is the predicted tissue (C T ) to blood (C b ) concentration ratio of total drug for each tissue. The organ volumes used were obtained from a review of the literature and are presented in Table 1 . If only unbound un-ionized drug is able to permeate cell membranes, then the concentrations of unbound unionized drug in tissue and blood will be equal at steady state (pH partition hypothesis), and for each tissue (eq. 3):
where f ub is f up /BP. Predicted plasma V ss was then calculated by dividing the predicted blood V ss by BP. For comparison, V ss was also calculated according to the tissue composition equations proposed by Poulin and Theil (2002) and corrected by Berezhkovskiy (2004) (or "method 1") and Rodgers et al. (2005) and Rodgers and Rowland (2006) (or "method 2"), as programmed in Simcyp Rat (version 8.0; Simcyp Ltd.) . Please refer to these publications for a detailed description of their approaches.
Results
Fractions Unbound and Un-Ionized in Blood and Tissues. The physicochemical properties used to calculate fraction un-ionized in blood and tissues are shown in Table 2 . Table 3 shows the fractions unbound in plasma and tissues as determined by ultracentrifugation, the in vitro blood/plasma concentration ratios, and the calculated fractions un-ionized in blood and tissues. The fractions unbound in plasma covered a wide range of values from 0.10% free (TC7) to 80% free (metoprolol). The fractions unbound in tissue homogenates corrected for dilution also covered a wide range of values from 0.037% free (TC4 in heart) to 100% free (lidocaine in several tissues). The calculated fraction un-ionized ranged from very low (strongly acidic and strongly basic compounds) to completely un-ionized (neutral compounds). For acidic compounds, the calculated fraction un-ionized was higher in the tissues, where the pH tends to be lower (tissue intracellular pH was estimated to be 7.0 versus A, acids; B, bases; N, neutrals; Z, zwitterions. a Compounds were considered to be neutral if they were primarily un-ionized around physiological pH, i.e., pK a Ͻ 7.4 for bases and pK a Ͼ 7.4 for acids. dmd.aspetjournals.org 7.4 in the blood) (Roos and Boron, 1981; Harashima et al., 1984; Rodgers et al., 2005) . For strongly basic compounds (pK a Ͼ 7.4), the calculated fraction un-ionized was higher in blood.
There was a loose trend that the higher the clogP, the lower the free fraction in tissues and plasma. However, the overall correlation was weak (r 2 Ͻ 0.6) ( Table 4) . Compounds with a low free fraction in one tissue tended to have a low free fraction in plasma or other tissues (Table 3) . However, the correlation between tissues and plasma was also weak (r 2 Ͻ 0.6) ( Table 4 ). The fraction unbound in some tissues showed a strong correlation (i.e., r 2 Ն 0.95) to the fraction unbound in other tissues. For example, the binding to kidneys showed a strong relationship to the binding in brain, heart, testes, and spleen. On the other hand, the binding in several tissues showed only weak relationships to the binding in other tissues (r 2 Ͻ 0.85), including bone, adipose, skin, pancreas, and intestine. Predicted V ss . The set of compounds studied included acidic, neutral, and basic compounds with a wide range of physicochemical properties (Table 2 ) and observed V ss in rats (Table 5) , ranging from 0.095 l/kg (TC6) to 73 l/kg (ethinylestradiol). V ss was predicted from in vitro tissue-binding data according to the equations shown under Materials and Methods. For comparison, V ss was also calculated according to the tissue composition equations proposed by Poulin and Theil (2002) and corrected by Berezhkovskiy (2004) (method 1) and by Rodgers et al. (2005) and Rodgers and Rowland (2006) (method 2), as programmed in Simcyp Rat (version 8.0; Simcyp Ltd.) . A common measure of prediction performance is to describe the number of compounds that fall within 2-or 3-fold accuracy. Such performance data can be observed in Fig. 2 and Table 6 . Several compounds were predicted within 2-fold regardless of the method, including cefazolin, cefoperazone, cyclosporine, TC3, diazepam, TC8, verapamil, and propafenone. Considering all compounds tested, predictions from tissue binding, method 1, and method 2 resulted in 61, 42, and 53, respectively, falling within 2-fold, and 81, 64, and 67%, respectively, falling within 3-fold prediction accuracy (Table 6 ). The best prediction (i.e., lowest -fold error) was obtained by TB, method 1, and method 2 for 44, 19, and 36% of the compounds, respectively. However, several compounds were not predicted well by any of the methods, including diclofenac, ethinylestradiol, TC4, and dasatinib, each with -fold errors of approximately 3 or greater.
Discussion
In this study, we investigated the feasibility of using in vitro tissuebinding data to quantitatively predict V ss in rats. It was found that in vitro determinations of nonspecific binding to components of blood and individual tissue homogenates, combined with estimated ionic effects of dmd.aspetjournals.org tissue-to-blood pH gradients, could accurately predict V ss within 3-fold for 81% of the wide range of compounds studied. On a technical note, an ultracentrifugation technique was used to determine the free fractions of drugs in plasma and tissue homogenates. This method was chosen after preliminary studies exposed potential limitations in using equilibrium dialysis techniques for tissue binding studies, versions of which have been reported previously (Clausen and Bickel, 1993) . Such limitations included long incubation times required to reach equilibrium for many drugs and loss of homogeneity in the tissue preparations, sampling problems, and tissue decay over long incubation times. The microscale ultracentrifugation technique (Nakai et al., 2004) allowed for a more robust experimental design and better capacity to work with a wide range of drugs and tissues. Of course, we realize that different separation methods as well as interlaboratory differences in technique can lead to slightly different measurements of protein binding. Hence, we elected to determine all binding parameters using a single technique, even though plasma protein binding values for many drugs were already reported in the literature.
It is interesting to note that predictions including tissue-binding measurements but excluding effects of a tissue-to-blood pH gradient resulted in a somewhat less accurate set of predictions for acidic and strongly basic compounds (figure not shown). Excluding the fraction un-ionized terms from calculations led to the underprediction of V ss for most of the strongly basic compounds by 2-to 4-fold. Per the pH partition hypothesis, such pH gradients have been thought to enhance the partition of basic drugs into tissues and certain subcellular organelles, such as lysosomes, whereas the pH tends to be lower than that in blood (Harashima et al., 1984; Yokogawa et al., 2002; Gong et al., 2007) . This observation led to the incorporation of pH effects into modified tissue composition equations that, among other modifications, helped to improve the prediction of V ss for strong bases using physicochemical property data (Rodgers et al., 2005) . Excluding the fraction un-ionized terms from calculations also led to the overprediction of V ss for several of the acidic compounds by 2-to 4-fold using tissue-binding data. Many acidic compounds, such as lactam antibiotics, have poor penetration into intracellular tissue spaces leading to low K p ratios and V ss (Tsuji et al., 1983) . This result may be due to a combination of poor membrane permeability as well as the ionic effects of tissue-to-blood pH gradients, which both effectively limit tissue partitioning. Therefore, incorporating the fraction un-ionized terms in the calculations led to improved prediction of V ss for many acidic compounds. In contrast, the fraction un-ionized terms yielded little effect on the predictions of compounds that are primarily un-ionized around physiological pH.
Some differences were noted in the relative performance of predictions from tissue binding data and predictions from the two tissue composition approaches (method 1 and method 2). The improvements made by method 2 over method 1 have been described previously (Rodgers et al., 2005) . In our hands the prediction accuracy was also somewhat improved with method 2 versus method 1, particularly for acids and bases (Table 6 ). However, it should be noted that the calculated logP and pK a values rather than experimental values were used, which can lead to some differences in predictions relative to those that were reported previously. We elected to use calculated values because, in the discovery and early development setting, definitive experimental values are rarely available, as was the case with the Amgen proprietary compounds. Therefore, for consistency, we used clogP for all compounds. Considering all compounds, predicting V ss using tissue binding data appeared to significantly improve prediction success compared with method 2. Predictions from tissue binding and method 2 resulted in 81 and 67% of the compounds, respectively, falling within 3-fold prediction accuracy (Table 6 ). The apparent improvement in overall accuracy by the tissue binding method was primarily driven by improvements in the prediction of V ss from neutral compounds, which were mostly novel Amgen proprietary compounds. Method 2 dramatically overpredicted the V ss for TC4 and nicardipine, whereas tissue binding did a much better job of estimating V ss for these and other neutral compounds. TC4 and nicardipine had the highest clogP values of the compounds tested (Table 2 ). It could be that calculation of logP inaccurately estimated the true logP in these cases or that Method 2 is less accurate when one is predicting V ss of highly lipophilic (Rodgers and Rowland, 2007) . Further study is warranted to characterize these limitations. The predictive performances for acids and bases were similar between the tissue binding method and method 2. Finally, the V ss for some compounds was not accurately predicted by the tissue binding method described here. Inaccurate predictions by this method could be a result of inaccurate determinations of fraction unbound [possible example: TC4, which was estimated to be Ͼ99.9% bound in several tissues (Table 3) ] or violations of the assumptions outlined under Materials and Methods. In particular, tissue binding and ionic effects failed to accurately predict V ss for compounds such as diclofenac and ethinylestradiol. These compounds are known to undergo substantial enterohepatic recycling (Back et al., 1980; Fukuyama et al., 1994) . Enterohepatic recycling acts as another compartment into which drug can distribute, prolongs the terminal half-life and increases the observed V ss (Roberts et al., 2002) . In fact, cannulating the bile duct in rats reduced the observed volume of distribution of diclofenac by approximately 4-fold compared with that of intact rats (Fukuyama et al., 1994) . Therefore, tissue binding can reasonably predict V ss for compounds for which enterohepatic recycling is minimal, and a lack of prediction can warrant further study of such mechanisms.
In summary, the present work demonstrated that using in vitro tissue binding experiments to estimate V ss is feasible for a wide range of compounds. This in vitro approach can complement the existing tissue composition equations when one is predicting V ss in the preclinical setting.
